Avidity Biosciences (RNA) Total Current Liabilities (2019 - 2025)
Historic Total Current Liabilities for Avidity Biosciences (RNA) over the last 7 years, with Q3 2025 value amounting to $169.9 million.
- Avidity Biosciences' Total Current Liabilities rose 8599.96% to $169.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $169.9 million, marking a year-over-year increase of 8599.96%. This contributed to the annual value of $98.0 million for FY2024, which is 2148.98% up from last year.
- As of Q3 2025, Avidity Biosciences' Total Current Liabilities stood at $169.9 million, which was up 8599.96% from $135.1 million recorded in Q2 2025.
- Avidity Biosciences' Total Current Liabilities' 5-year high stood at $169.9 million during Q3 2025, with a 5-year trough of $16.3 million in Q2 2021.
- Over the past 5 years, Avidity Biosciences' median Total Current Liabilities value was $48.7 million (recorded in 2023), while the average stood at $63.5 million.
- Per our database at Business Quant, Avidity Biosciences' Total Current Liabilities surged by 10618.8% in 2022 and then surged by 1322.13% in 2025.
- Avidity Biosciences' Total Current Liabilities (Quarter) stood at $29.7 million in 2021, then surged by 75.02% to $51.9 million in 2022, then soared by 55.43% to $80.7 million in 2023, then increased by 21.49% to $98.0 million in 2024, then surged by 73.31% to $169.9 million in 2025.
- Its Total Current Liabilities was $169.9 million in Q3 2025, compared to $135.1 million in Q2 2025 and $84.9 million in Q1 2025.